Myriad Genetics (NYSE:MYGN) Price Target & New Coverage by Goldman Sachs
Research analysts at Goldman Sachs began coverage on shares of Myriad Genetics (NYSE:MYGN) in a report shared with investors and clients on 29 January. The firm set “Sell” rating on the stock. Goldman Sachs’s target price per share of $32.0 suggests potential of -21.97 % from the stock’s current stock price.
After the coverage NYSE:MYGN is currently trading 0.00% lower at $0.00 as of 10:05 AM New York time. Myriad Genetics’s stock is 0% over the last 200 days. It has underperformed the Standard & Poor’s 500 index, which has surged 6.00% over the same time.
According to data compiled by Thomson Reuters, Myriad Genetics (NYSE:MYGN)’s stock is covered by 12 equity analysts across the Street, with 3 analysts giving it a Sell rating, 8 a Buy rating, while 7 consider it a Hold. The 12-month consensus target price for the stock is $39.58, which reflects an upside potential of ∞% over the current price.
Tieton Capital Management Llc had the largest stake with ownership of 194,015 shares as of q2 2015 for 3.43% of the US long stock exposure. North Tide Capital Llc is another bull as the investment manager who is having 1.00 million shares of Myriad Genetics or 2.24% of their US long stock exposure. Also, S&T Bank Pa have 2.2% of their US long stock exposure invested in the company for 644,837 shares. The New York-based fund Consonance Capital Management Lp disclosed it had bought so far a stake worth about 1.68% of the investment manager’s stock portfolio in Myriad Genetics. The California-based fund Aimz Investment Advisors Llc is also positive about the stock, possessing 850,000 shares or 0.82% of their US long stock exposure.
Myriad Genetics (NYSE:MYGN) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. Myriad Genetics has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.
Get the latest Myriad Genetics (NYSE:MYGN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Myriad Genetics (NYSE:MYGN) Now Covered by Goldman Sachs. The Price Objective is $32.0 appeared first on Octafinance.